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Introduction 
Permanent intestinal failure was a challenging 
clinical entity for decades. The introduction of total 
parenteral nutrition (TPN) by Dudrick in 1968 
opened a new horizon of life support for patients once 
considered to have terminal prognoses. Unfortu-
nately, chronic, prolonged TPN is not without haz-
ards; eventually the majority of TPN-dependent pa-
tients lose their liver secondary to TPN -induced 
cholestasis and subsequent irreversible liver damage. 
Isolated orthotopic liver transplantation is not indi-
cated, since the need for TPN will persist, with subse-
quent damage to the new liver. Venous access for de-
livery of TPN can be a serious problem, especially in 
children, in terms of both line sepsis and venous site 
availability. Long-term expenses for lifetime homel 
hospital TPN is an added limitation. 
Although the small bowel was part ofthe compos-
ite of organs to be experimentally transplanted early 
in the 1960s, it is the last transplantation to be clini-
cally successful. Rejection, infections, and technical 
complications were the main obstacles to earlier suc-
cess. Thirty years of experimental and clinical re-
search preceded the successful series of small bowel 
transplantations at the University of Pittsburgh (39 
patients through March 1993). Technical refinement, 
innovative immunosuppression, and better postoper-
ative management will help achieve a reproducible, 
consistent cure. Small bowel can be transplanted 
alone, combined with a liver transplant, or trans-
planted as part of multivisceral graft. The cecum, 
ileocecal valve, and colon can also be included. 
Indications for Small 
Bowel Transplantation 
Failure to support bodily needs through water and 
caloric intake by enteral route alone mandates small 
bowel transplantation. Causes include short gut syn-
drome, dysfunctional small bowel, and some non-
short gut/nondysfunctional conditions. 
SHORT GUT SYNDROME 
The minimum length of small bowel necessary to 
maintain adequate enteral absorption of water and 
nutrients is not well established. It varies between 10 
and 20 cm in presence of ileocecal valve and colon and 
40 cm without them. 
DYSFUNCTIONAL SMALL 
BOWEL 
Dysfunction in the small bowel may be due to 
either absorptive insufficiency (e.g., microvillous in-
clusion enteropathy) or motility disorders, including 
total intestinal aganglionosis (total Hirschspiung's 
disease), defective ganglionosis, and intestinal 
pseudo-obstruction (microcolon, megacystis syn-
drome, holovisceral myopathy or Sieber syndrome). 
NON - SHORT GUT / 
NONDYSFUNCTIONAL 
INDICATIONS 
There are other situations in which enteral nutri-
tion would fail: (1) diffuse splanchnic vessel thrombo-
sis without short gut, making isolated orthotopic liver 
transplantation impossible because of the lack ofpor-
tal inflow; and (2) pancreatic tumors with lymph node 
involvement around the celiac trunk or the superior 
mesenteric artery (SMA), with an otherwise negative 
metastatic work-up. The latter is usually a part of an 
extended upper abdominal exenteration and multivis-
ceral transplantation. . 
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Pretransplantation 
Evaluation 
The patient selection process begins with a de-
tailed history, including previous surgical procedures, 
and a thorough physical examination for signs ofpor-
tal hypertension or endstage liver disease, with ancil-
lary work-up as needed. 
mesenteric vein (SMV) thrombosis, portal vein 
thrombosis, Budd-Chiari syndrome), Doppler ultra-
sonography, magnetic resonance imaging (MRI), an-
giography, and venous phase portography are neces-
sary so as to be able to tailor the procedure according 
to the pre-existing vascular condition. Portal vein or 
even SMV occlusion are not contraindications for 
transplantation; since a multivisceral transplant can 
be performed after resection of the. native intra-
abdominal organs. 
In patients with vascular occlusive syndromes 
(chronic mesenteric vascular occlusion, superior 
Notably, the neck and upper- and lower-extrem-
ity vessels should be eV,aluated, especially in patients 
Management of Patient Selection 
Dependence on total parenteral nutrition 
Actual Predicted 
~~ 
Reversible liver injury Irreversible liver injury 
~ ~ 
Elevated transaminases 
Hyperbilirubinemia 
Cholestasis 
~ 
Weanable from total 
parenteral nutrition 
~ 
Adaptation (?) of existing 
small bowel 
~ 
No need for therapy 
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Persistent dependence 
on total parenteral 
nutrition (failure of 
conservative treatment) 
With fibroSis/cirrhosis, 
portal hypertension, 
splenomegaly, varices 
~ 
Combined liver and 
small bowel transplantation 
with or without right colon 
With preservation of 
duodenum, pancreas, 
and liver 
~ 1 
Solitary small bowel 
transplantation with or 
without right colon 
Inevitable total enterectomy 
With resection of stomach, 
duodenum, pancreas, 
and liver 
1 
Multivisceral transplantation 
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with a history of multiple central lines or vascular 
thrombosis, to ensure adequate vascular access for 
intraoperative management and monitoring. 
In addition, the following evaluations are re-
quired: 
Nutritional assessment: Necessary baseline informa-
tion regarding the pretransplantation nutritional 
status of the patient includes a complete dietary 
and weight history and a growth curve. Use of 
TPN and any oral/enteral supplements is 
recorded; serum levels of vitamin, minerals, and 
trace elements are checked. 
Blood typing: Tissue typing (human lymphocyte anti-
body [HLA]) is done, as is testing for panel reac-
tive antibodies (PRA). 
Virologic evaluation: This includes cultures and titers 
(lgG, IgM) for cytomegalovirus, Epstein-Barr 
virus, herpes, varicella, and mumps, and screen-
ing for human immunodeficiency virus (HIV) and 
hepatitis. 
Psychiatric/social service evaluation: Patient/family 
emotional stability and the existence of support 
systems should be determined to ensure postop-
erative patient compliance. 
Preoperative 
Management 
Preoperative management is based upon 6 main 
goals, as follows: 
1. Maintainance of adequate nutrition with adequate 
vitamin, electrolyte, and trace element levels 
2. Maintainance of pre-existing oral feeding if appli-
cable or establish oral use if possible, even ifnutri-
tional value of intake is doubtful or nil. Patients-
especially children - who do not develop oral 
intake habits face significant post-transplantation 
difficulty in starting oral feeding 
3. Prevention (if possible) of progression of liver 
damage that is due to TPN dependence from re-
versible to irreversible. Cyclic TPN, low-dextrose-
content TPN, and simultaneous enteral feeding 
are among measures that lower the risk of TPN-
induced endstage liver disease 
4. Prevention and treatment of central line-
associated sepsis by adopting a strict aseptic tech-
nique of handling home/hospital TPN and by per-
forming surveillance quantitative stool cultures to 
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monitor signs of bacterial/fungal translocation. 
Selective decontamination of the digestive tract is 
advisable under these circumstances to prevent 
systemic and fulminant bacterial/fungal lethal in-
fections 
5. Management of hepatic dysfunction as necessary. 
Methods include control of encephalopathy by 
regulation of ammonia levels through lowering of 
the amino acid content in TPN; the use of enteral 
lactulose, if applicable); the use of plasmapheresis 
(the value of which has been limited, with a moder-
ate rate of success); administration of clotting fac-
., tors (fresh-frozen plasma or cryoprecipitate) to 
correct prolonged prothrombin time; and counter-
acting the hematologic effect of hypersplenism 
with blood and platelet transfusion 
6. Management of variceal (esophageal, gastric, or 
stomal) bleeding by sclerotherapy, continuous in-
fusions of vasopression, or continuous infusion of 
somatostatin. 
Cadaveric Organ 
Procurement 
Organ donors are matched by ABO grouping and 
size match. There is no minimum age limit. An ab-
sence of liver disease (determined by history and bio-
chemical testing), as well as freedom from infection, 
are mandatory. In the presence of a normal liver, no 
functional or anatomic assessment of the intestine is 
required. The HLA matching is random. Attempts to 
mechanically cleanse the bowel are not performed 
unless the colon is to be included in the graft; however, 
if this is necessary, a tap-water enema is performed 
prior to harvesting. A solution containing amphoteri-
cin B, tobramycin, and polymyxin E is administered 
via a nasogastric tube. Ablation of the gut-associated 
lymphoid tissue (GALT) is not performed. Systemic 
antibiotics and selective decontamination of the gut 
prior to the harvesting procedures, using the regimen 
outlined in Table 1, is started once the donor is identi-
fied and repeated every 6 hours if time permits. 
The success of the harvesting procedure depends 
on the presence of one or two central stems: the supe-
rior mesenteric artery in harvesting for an isolated 
small bowel transplant, or the celiac axis and superior 
mesenteric artery in harvesting for the en-block liver 
and small bowel or multivisceral transplant. 
Perfusion of the graft using University of Wis-
consin (UW) solution is performed through the infra-
renal aorta and portal vein. The venous outflow is 
UPl-1O/93 
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TABLE 1 
INTESTINAL DECONTAMINATION FOR 
DONOR AND RECIPIENT 
ANTIBIOTIC' DOSAGE 
<5 Yrs (mg) 5-12 Yrs (mg) > 12 Yrs (mg) 
Amphotericin B 100 250 500 
Tobramycin 10 40 80 
Polymyxin E 25 50 100 
• Systemic antibiotics: cefotaxime, 25 mg/kg/dose tid IV; ampicillin, 25 
mg/kg/dose qid IV. 
drained through the inferior vena cava either in the 
chest (most common) or in the abdomen (less com-
mon). Figs. lA, 2A, and 3A show different possibilities 
of harvesting; Figs. lB, 2B, and 3B depict recipient 
operations (discussed below). 
Small bowel can be harvested with the liver in 
continuity to be used as a combined liver and small 
bowel transplant graft or to be separated for use in two 
separate recipients (i.e., an orthotopic liver trans-
plantation and an isolated small bowel transplanta-
tion). 
If the extent of the final transplant is still in ques-
tion (requiring intraoperative evaluation), it is advis-
able to harvest the graft as multi visceral organs (i.e., 
stomach, duodenum, liver, pancreas, small bowel, and 
colon in continuity). Recently, we have included the 
colon in the graft to help overcome defective water 
absorption with subsequent high ileostomy output. 
Operative Decisions 
and Techniques 
The extent and the degree of liver disease is usu-
ally established preoperatively. When doubts about 
the status of the liver exist, a needle biopsy and a 
frozen section obtained during the operation is help-
ful. The presence of cirrhosis mandates hepatectomy. 
In functional small bowel failure (absorption/motil-
ity), the operative evaluation, in addition to preoper-
ative findings, will help the surgeon reach a decision 
regarding the extent of resection/replacement. Also, 
frozen-section biopsy of the mesenteric/pancreatic 
lymph nodes helps establish the operatibility of 
tumors. 
The recipient procedure entails arterialization of 
the graft via an end-to-side arterial graft anastomosis 
to the infrarenal aorta. The SMV of an isolated small 
bowel graft can be anastomosed end-to-end to the 
superior mesenteric vein of the recipient or can be 
anastomosed end-to-side to the recipient portal vein 
(piggyback). 
In combined liver and small bowel grafts, no por-
tal or SMV anastomosis is required, as the graft is 
harvested en-bloc. The recipient portal vein draining 
the native pancreas and duodenum can be anasto-
mosed either to the inferior vena cava (IVC) (portaca-
val shunt) permanently or temporarily. It can also be 
drained to the graft portal vein in end-to-side fashion. 
The outflow of the liver drains through the supra-
hepatic vena cava to the recipient's hepatic veins, 
which are fashioned into a single stoma (piggyback), 
Notably, the recipient IVC is left uninterrupted 
through a meticulous hepatectomy sparing the retro-
hepatic inferior vena cava (piggyback technique). 
(See Figs. lB, 2B, and 3B for the various surgical 
options.) 
Postoperative 
Management 
REJECTION PREVENTION 
The introduction of the immunosuppressive agent 
FK-506 in 1989 facilitated dramatic improvement 
in the success of clinical small bowel transplantation. 
This is due to not only to the greater potency of FK-
506 versus Cyclosporin A, but also because the ab-
sorption characteristics ofFK-506 after oral adminis-
tration are less influenced by the presence or absence 
of bile and bile acids than by the motility and function 
of the intestine itself. Immunosuppression is induced 
by the administration of 0.1 to 0.15 mg/kg/d of FK-
506, continuous intravenous (IV) infusion, starting as 
soon as graft revascularization is complete, until an 
FK-506 plasma level of between 2 and 3 ng/ml is 
reached. Adults require one-third of the dose to 
achieve similar levels. Once intestinal motility is re-
gained, oral FK-506 is started at 0.3 mg/kg/d in two 
divided doses. A 24- to 48-hour overlap period is usu-
ally required before adjuvant steroid therapy can be 
discontinued under one of two regimens: 
1. 1 g IV hydrocortisone is given during the opera-
tion, followed by 100 mg IV methyl prednisone, 
tapered over a 5-day course to 20 mg/d IV. This 
baseline dose is then tapered slowly to weaning, 
which averages 4.6 weeks. 
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B 
Figure 1. Isolated small bowel transplantation. (A) Donor operation with full-length vascular pedicle of the 
superior mesenteric artery (SMA) (with Carrel patch) and the superior mesenteric vein (SMV). Ifboth vessels 
are divided more distally, they can be lengthened on the back table with arterial and venous grafts (inset). 
(B) Recipient operations: anastomosis of full-length SMA to the aorta and the angled end of the SMV to the 
portal vein (PV); alternative method, in which the SMV is anastomosed to the recipient SMV inferior to the 
pancreas (lower inset); option of SMV drainage into the inferior vena cava (Ve) (upper inset). (From Todo S, 
Tzakis AG, Abu-Elmagd K et al: Intestinal transplantation in composite visceral grafts or alone. Ann Surg 
216:223, 1992, with permission.) 
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A B 
Figure 2. Small bowel-liver allograft. (A) Donor operation. Note the continuity of donor portal vein. 
(Abbreuiations: CA, celiac axis; IVC, inferior vena cava; PV, portal vein; SMA, superior mesenteric artery.) 
(B) Recipient operation. Carrel patch containing the origin of the superior mesenteric artery and the celiac 
axis is anastomosed to the aorta. Ideally, the venous return from residual splanchnic viscera of the recipient is 
routed by vascular anastomosis into the graft portal vein. Numerous options of graft rearteriaiization and 
venous drainage have been described in other texts. (From Todo S, Tzakis AG, Abu-Elmagd K et al: Intestinal 
transplantation in composite visceral grafts or alone. Ann Surg 216:223, 1992, with permission.) 
2. A baseline dose of methylprednisone, 20 mg/d IV, 
is given for patients weighing more than 10 kg; the 
baseline dose for those less than 10 kg is 10 mg/d. 
The steroid is then tapered slowly to weaning over 
4 to 6 weeks. 
When enteral/oral feeding is achieved, methyl-
prednisone is replaced by oral prednisone. The first 
regimen (above) is always used for isolated small 
bowel transplantation and for grafts including the 
right colon, while the second regimen (above) is used 
in combined liver and small bowel transplants. 
In addition to FK-506 and steroids, prostaglandin 
El (PGE1 ) is administered at 0.003 to 0.009 p.g/kg/ 
min IV continuous infusion for a minimum of 5 days 
to reduce FK -506 nephrotoxicity and to aid in immu-
nosuppression. 
REJECTION MONITORING 
Liver function tests and liver biopsies, in addition 
to clinical physical examination, help monitor liver 
rejection. Rejection of the small bowel and colon are 
detected by monitoring the patient's clinical picture, 
stoma output, and stoma color. Stomal endoscopy and 
biopsy can be performed as frequently as twice a week 
if the index suspicion for rejection is high. 
Table 2 shows the correlation of clinical, endo-
scopic, and histologic findings in different stages of 
small bowel rejection. 
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A B 
Figure 3. Multivisceral allograft (A) before and (B) after transplantation. Splenectomy is performed on the 
back table. In this case the Carrel patch, with the superior mesenteric artery and celiac axis origins, has been 
used to cap a free graft of donor thoracic aorta that has been used as a conduit. This is only one of several 
options that the operator should be prepared to exercise. (Abbreviations: IVC, inferior vena cava; PV, portal 
vein.) (From Todo S, Tzakis AG, Abu-Elmagd K et al: Intestinal transplantation in composite visceral grafts 
or alone. Ann Surg 216:223, 1992, with permission.) 
REJECTION CONTROL 
Mild to moderate acute cellular rejection is 
treated with an increased FK-506 dosage, a bolus of 
steroids, or a steroid-tapering recycle. OKT3 may be 
used in severe acute cellular rejection. Multiple epi-
sodes of moderate acute cellular rejection, especially 
in the presence of renal dysfunction, may warrant the 
addition of azathioprine to augment baseline immu-
nosuppression. 
Documentation of chronic rejection by angio-
graphic and histologic changes showing arteritis obli-
terans and mucosal microabscesses mandates resec-
tion of the graft and retransplantation, if possible. 
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INFECTION PREVENTION 
AND TREATMENT 
The key to successful small bowel transplanta-
tion is infection control. The bowel is the nutrient-
transporting organ, and also acts as a barrier against 
entry of pathogens into the body, which is achieved by 
the fundamental structure of the gut and GALT, 
comprising CD4+ and CD8+ T cells, B cells, macro-' 
phages, M cells, and natural killer (NK) cells. 
Normally, pathogens (bacterial and fungal) living 
inside the gut lumen pass through the epithelial mu-
cosa into the lamina propria and then to the mesen-
teric lymph nodes and possibly other tissues with the 
UPl-1O/93 
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TABLE 2 
MONITORING OF INTESTINAL GRAFT REJECTION 
REJECTION 
Acute (mild to 
moderate) 
CUNICAL FINDINGS ENDOSCOPIC FINDINGS 
Fever Ischemic/dusky mucosa 
Abdominal pain Mucosal edema 
Vomiting Hyperemia 
Increase of stomal loss of fine mucosal pattern 
output ,- Decrease of peristalsis 
IKID:I~ Watery diarrhea . .,! 1-:;', ,rF:., . ,I). ,:;, 
1fI~~!_~ KI:r;f~ ''i.>\. ~;~~·IrKi ":i'- ;~~I~ ?:fDfrt:i~:_i"I!~;:r=rl<D;D" 
Severe 
Chronic 
Severe diarrhea ",' 
Abdominal pain 
Abdominal distension 
" Metabolic acidosis 
Positive blood culture 
Adult respiratory 
distress syndrome 
Chronic diarrhea 
Malabsorption 
Progressive weight loss 
~rlcerationI ; ;1 
Mucosal sloughing., 
Bleeding "., L "v, 
Loss of peristalsis' 
Pseudomembrane 
Hypoperistalsis 
Loss of mucosal fold 
Oily intestinal contents 
MUCOSAL BIOPSY 
FINDINGS 
Cell infiltration 
Villus blunting 
Cryptitis 
Epithelial cell damage and 
, regeneration 
j¥rcus/m~th cell r~~ction 
)-n::r';l;, b!Tlj t~;~b:FD~~!:-: 
Mucosal hemorrhage ; , 
Mucosal sloughing . 
Microabscess ' ; :',. [ • 
Fewer inflammatory cells 
Evident cryptitiS 
Regenerative epithelium 
Submucosal fibrosis 
(suggestive but not 
conclusive)' 
" ~K:;giKh~K-;;;-~;}I D~-"::Dl 
,d :,,:i &t<,.'1 !.; "IF~kKl J.\ 
',i. D:DfIi;KlfmlKaD1i~D~Dq 
"j '" D;"1r:F·tKr~t~ ;~iqK~j~ 
, I1~tk!Di 10' ~m1 ':.vt 
:D>~ig 
, Histologic diagnosis of chronic rejection is made with the resected graft, which shows arteritis obliterans and 
mucosal abscess. 
(Modified from Todo S, Tzakis AG, Abu-Elmagd K et al: Intestinal transplantation in composite visceral grafts or alone. 
Ann Surg 216:223, 1992, with permission.) 
help of macrophages. This is an active process, used 
for sampling purposes as part of immunologic sur-
veillance. In transplanted bowel, the combination of 
(1) immunosuppression, (2) repopulation of GALT 
with recipient cells, (3) bacterial and fungal over-
growth, and (4) cryptitis associated with acute cellu-
lar rejection enhances bacterial translocation beyond 
the physiologic mission intended. 
Monitoring of post-transplant quantitative stool 
cultures allows prediction of the organisms that will 
be associated with translocation. Growth of a single or 
minimal number of organisms greater than lOS colo-
nies/ g of stools is associated with a higher incidence of 
translocation. This rationale lies behind the policy of 
application of selective decontamination of the diges-
tive tract. Modification of the constituents of the an-
tibacterial/antifungal regimen is required according 
to the culture and sensitivity results of gut bacteria. 
We administer selective decontamination of the di-
gestive tract four times a day enterally for 6 to 8 weeks 
post-transplant and 2 weeks thereafter whenever 
acute cellular rejection of the bowel is documented. 
Intravenous broad-spectrum antibiotics are given for 
5 days after transplantation and whenever positive 
blood, urinary tract, or respiratory tract infections are 
documented. Central lines and catheters are changed 
as per routine infection control guidelines. 
NUTRITIONAL SUPPORT 
Total parenteral nutrition is continued postoper-
atively as soon as these patients are hemodynamically 
stable (24 to 48 hours) and continued as long as their 
enteral nutrition is inadequate (19 to 210 days-
mean, 65 days). Weaning from TPN is started when 
enteral intake reaches 50 percent of the caloric re-
quirement or when fluid status requires it. Reciprocal 
increase of enteral feeding and decrease of TPN is 
progressed gradually until freedom from TPN is 
achieved. A transitional period, when low-calorie or 
noncaloric intravenous fluids may still be needed to 
compensate for high stomal output, is dealt with on 
individual basis. One to 2 weeks of close monitoring of 
fluid and electrolyte balance is usually required before 
all intravenous fluids are discontinued and the pa-
tient is totally dependent on enteral intake of water, 
electrolytes, and calories. Enteral feeding is started 
when peristalsis ofthe transplanted bowel is regained 
and a radiologic contrast study documents patency of 
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the bowel with integrity of the intestinal anastomosis. 
Attaining this status usually takes 7 to 10 days. En-
teral feeding is established via a nasogastric, naso-
duodenal, gastrostomy, or jejunostomy tube, depend-
ing on the availability of the route. Continuous, 
gradually increasing feeds are preferred to bolus feeds. 
The ideal formula should have a low osmolality to 
prevent hyperosmolar diarrhea. The protein source 
should be in small peptide form to ensure rapid ab-
sorption. Extensive animal research has indicated 
that glutamine is a conditionally essential amino acid. 
It plays a role in acid - base balance; is an important 
precursor of nucleic acids, nucieotides, and amino 
sugars; and is considered to be the preferred respira-
tory fuel for enterocytes. The major proportion of fat 
contents ofthe ideal formula should be in the form of 
medium-chain triglycerides (MCT), so that it is ab-
sorbed directly without the need for lacteals and 
lymphalics. Standard commercial formulas, such as 
Vivonex TEN, Peptamen, Modified Compleat, and 
Alitraq, are used. Once the enteral feeding is estab-
lished, efforts are made to establish and encourage the 
oral route. It has been observed that patients, particu-
larly children, who have not been eating before trans-
plantation face difficult clinical problems in accept-
ing oral feeding, possibly due to a hyperactive, 
unsuppressed gag reflex; difficulty in swallowing; or 
psychologic factors. Cycling of tube feeding betters 
the chance of improvement of oral intake. 
Close observation of the stoma output, regarding 
volume, pH, presence of reducing substance (glucose), 
and quantity of bacterial/fungal overgrowth, is im-
TABLE 3 
MONITORING OF SMALL BOWL GRAFT 
FUNCTIONa 
FUNCTIONAL ASPECT TEST 
Carbohydrate absorption Testing of reducing substance 
in stoma output 
o-xylose absorption test 
Blood sugar level' 
Fat absorption 72-hour stool fat excretion 
Serum levels of vitamins A, 0, eo 
Protein absorption Serum albumin and prealbumin" 
Anthropometric measurements" 
General absorption Urine output" 
Serum zinc, magnesium, iron" 
FK-506 levels" 
Schilling tests 
• After weaning from total parenteral nutrition and intravenous 
therapy. 
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portant. Abnormalities in urine output, blood urea 
nitrogen (BUN), serum creatinine, electrolytes, and 
acid-base balance are treated promptly intra-
venously while the patient is still on intravenous 
fluids or enterally when weaned from intravenous 
fluids. In the absence of colon, there is usually a tend-
ency to lose water, sodium, magnesium, and bicar-
bonate, warranting excess supplementation with so-
dium citrate or bicarbonate and magnesium 
gluconate. Antidiarrheal drugs (e.g., loperamide and 
diphenoxylate) are useful for controlling rapid transit 
and increasing stomal output. Our experience with 
somatostatin analogues has not been encouraging. 
Pectin can also be used as a stool-thickening agent; 
with limited success. 
Monitoring of nutritional status once these pa-
tients are weaned from TPN and intravenous therapy 
can be achieved through monitoring of small bowel 
graft function, as shown in Table 3. 
Management of 
Postoperative 
Complications 
Postoperative complications can be classified as 
technical, immunologic, infectious, renal, respiratory, 
or recurrence of primary disease. Although efforts are 
made to prevent complications, they can occur, and 
should be treated promptly. 
TECHNICAL 
COMPLICATIONS 
Bleeding and gastrointestinal anastomotic leaks 
are the main possible technical problems, requiring 
exploration and appropriate management. Vascular 
thrombosis in pediatric patients is prevented by ad-
ministration of anticoagulants (aspirin, heparin, Per-
santin) once the prothrombin time is less than 17. 
Vascular strictures can be managed by transluminal 
balloon angioplasty. 
IMMUNOLOGIC 
COMPLICATIONS 
Rejection and graft-versus-host disease are pre-
vented and treated with augmentation of immuno-
suppression. 
UPI-IO/93 
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INFECTIONS 
Immunosuppression is to be dramatically reduced 
or even discontinued in presence of viral infections. 
Gancyclovir is used in the prevention, treatment of 
initial infection, and treatment of reactivation of cy-
tomegalovirus (CMV). Acyclovir is the drug of choice 
for treatment of Epstein-Barr virus (EBV), chicken-
pox, and viral herpes infections. The value of acy-
clovir oral chronic prophylactic therapy is still in 
question. Post-transplantation lymphoproliferative 
disease has been shown to be EBV -related. It alulast 
always responds to discontinuation'·ofun.munostlP-
pression and intravenous administration of acyclovir. 
Adenovirus and influenza viruses can be lethal, espe-
cially when they occur early postoperatively. The lack 
of specific treatment may playa role in their develop-
ment. Intravenous immunoglobulin, Ribavirin, or 
Amantadine may be used when appropriate. Bacterial 
and fungal infections are dealt with as usual, using the 
drugs indicated by sensitivity studies. Selective de-
contamination of the digestive system (SDD) is ad-
ministered to reduce the chances of translocation as 
the source of these infections. 
RENAL COMPLICATIONS 
Renal impairment is prevented by adequate mon-
itoring of the fluid balance and of nephrotoxic drug 
levels (e.g., antibiotics and antifungal and antirejec-
tion agents). Prostaglandin E (PGE) and dopamine 
may be helpful at a renal dose. Short-term hemodial-
ysis can be used. 
REspmATORY 
COMPLICATIONS 
Infections such as Pneumocystis carinii pneumo-
nia are prevented by prophylactic administration of 
trimethoprim sulfa. Pentamidine can be used in the 
presence of an allergy to trimethoprim sulfa; dapsone 
can be used in those allergic to trimethoprim sulfa 
who cannot tolerate pentamidine inhalation. Intrave-
nous trimethoprim sulfa or pentamidine are the drugs 
of choice for the treatment of this fatal infection. 
Mechanical ventilation, and respiratory physio-
therapy are crucial in the management of po stop era-
tive infection or mechanical respiratory problems. 
When medical management by diuretics and albumin 
fails, drainage of pleural effusion can be achievd by 
insertion of a pigtail catheter. 
RECURRENCE OF THE 
PRIMARY DISEASE 
So far we have not seen recurrence of intestinal 
pseudo-obstruction or microvillous inclusion enter-
opathy. A recipient of an isolated small bowel for ad-
vanced Crohn's disease lost his graft 12 months post-
transplant because of chronic rejection, rather than 
recurrence of Crohn's disease. 
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'Between May 1990 and March 1993; 39 patients 
underwent small bowel transplantation' at the Uni-
versity of Pittsburgh Medical Center. Twenty were 
adults and 19 were children. Tables 4 and 5 show the 
demographic breakdown, type of operation, follow-up 
period, and results of both the mediatric and adult 
groups. 
Conclusions 
The Pittsburgh experience in small bowel trans-
plantation shows that the results of this procedure are 
now more reproducible than before. This may be due 
to the availability of the potent immunosuppression 
agent FK-506, and to a better understanding of the 
two-way traffic of dendritic cells and lymphocytes 
that happens immediately following small bowel 
transplantation. This allows donor lymphocytes to be 
replaced by recipient ones in the GALT, forming a 
mixed chimerism. Alteration of the balance between 
these two components leads to the development of 
graft-versus-host disease. The Pittsburgh experience 
also shows that solitary small bowel transplantation 
is feasible. and that the relative simplicity and safety 
of this procedure outweighs the potential immuno-
logic advantage provided by the liver in combined 
liver and small bowel transplantation. The addition of 
the liver is reserved for endstage liver disease or in 
presence of an inborn malfunction in the liver, such as 
protein C deficiency. 
Lastly, a longer follow-up period is required to 
evaluate and plan prevention measures and a strategy 
for treating the infections and handling the technical 
complications associated with small bowel transplan-
tation. 
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TABLE 4 
SMAll BOWEL TRANSPLANTS: PEDIATRIC EXPERIENCE AS OF 
MARCH 15, 1993 
AGE SEX NATIVE DISEASE GRAFT PATIENT GRAFT TPN STATUS 
SURVIVAL SURVIVAL 
(DAYS) (DAYS) 
3.2 F NEC SB+L >965 >965 Free 
4.3 M Gastroschisis SB+L >842 >842 Free 
2.8 M Intestinal atresia 
.. 
SB+L 385 385 Died E~iaF 
.. : !" ~ D~ . 
0.6 F Intestinal atresia SB+L 23 23 Died (GVHD) 
1.1 F Volvulus SB+L >583 >583 Free 
1.7 F Volvulus SB+L >581 >581 Free 
2.5 F Microvillous inclusion SB >491 >491 Free 
enteropathy 
1.3 M Intestinal atresia SB >446 >446 Free 
10.2 F Intestinal pseudo- SB >374 >374 Free 
obstruction 
1.5 M NEC SB+ L 70 70 Died (MSOF) 
4.2 F Gastroschisis SB+L >278 >278 Free 
1.4 M Gastroschisis SB+L 29 29 Died (sepsis) 
0.9 M Microvillous inclusion SB+L >237 >237 Free 
enteropathy> 
0.5 M Gastroschisis SB+L >231 >231 Free 
4.5 F Intestinal pseudo- MV+C >133 >133 Free 
obstruction 
3.6 M NEC SB+C+L >96 60 Free (rejection) 
>36 Retransplanted 
0.9 F Gastroschisis SB+C+L >91 >91 Partial 
15.5 M Volvulus SB+C+L >70 >70 Free 
3.0 F NEC SB+C+L >7 >7 Early 
(Abbreviations: GVHD. graft-versus-host disease; MY. multivisceral; NEC. necrotizing enterocolitis; MSOF, multisys-
tem organ failure; PTLD. post-transplant Iymphoproliferative disease; SB. small bowel; SB + L, small bowel + liver; 
SB + C + L. small bowel + colon + liver: TPN. total parenteral nutrition.) 
llPl-lO/93 
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TABLE 5 
SMALL BOWEL TRANSPLANTS: ADULT EXPERIENCE AS OF 
MARCH 15, 1993 
AGE SEX NATIVE DISEASE GRAFT PAnENT GRAFT TPN STATUS 
SURVIVAL SURVIVAL 
(DAYS) (DAYS) 
31.1 M Gunshot wound SB 776 667 Retransplant 
SB 71 Died (sepsis) 
26.7 F SMA thrombosis SB+L >955 >955 Free 
21.0 M Traftic accident SB+l >572 >584 PartIal 
32.0 M CA + SMA thrombosis MY >518 >518 Partial 
SO.O F Crohn's disease SB >423 >423 Free 
34.0 F Desmoid tumor SB >406 239 Graft removed 
38.0 M Crohn's disease SB 376 370 Graft removed 
Died (sepsis) 
22.0 F Crohn's disease SB >368 >368 Free 
25.0 M Desmoid tumor SB+L >294 >294 Free 
29.0 F Traffic accident SB >281 >281 Free 
24.0 M CA + SMA thrombosis MV >291 >291 Free 
20.0 F Traffic accident SB >281 >281 Free 
31.0 F CA + SMA thrombosis SB+L >216 >216 Free 
19.1 M Traffic accident SB+L >213 >213 Free 
44.0 F SMA thrombosis SB+L >189 >189 Free 
37.0 F Familial polyposis SB >108 >108 Free 
44.0 M Gastrinoma MV 49 49 Died (sepsis) 
39.0 M Crohn's disease SB+C >28 >28 Partial 
35.5 M Crohn's disease SB+C >22 >22 Early 
58.0 F Multiple intestinal SB+C >12 >12 Early 
resection 
(Abbreviations: CA, celiac axis; MV, multivisceral; SB, small bowel; SB + L, small bowel + liver; SB + C + L, small 
bowel + colon + liver; SMA, superior mesenteric artery; TPN, total parenteral nutrition.) 
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